Cargando…

Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial

The multimodal activities of farnesoid X receptor (FXR) agonists make this class an attractive option to treat nonalcoholic steatohepatitis. The safety and efficacy of tropifexor, an FXR agonist, in a randomized, multicenter, double-blind, three-part adaptive design, phase 2 study, in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanyal, Arun J., Lopez, Patricia, Lawitz, Eric J., Lucas, Kathryn J., Loeffler, Juergen, Kim, Won, Goh, George B. B., Huang, Jee-Fu, Serra, Carla, Andreone, Pietro, Chen, Yi-Cheng, Hsia, Stanley H., Ratziu, Vlad, Aizenberg, Diego, Tobita, Hiroshi, Sheikh, Aasim M., Vierling, John M., Kim, Yoon Jun, Hyogo, Hideyuki, Tai, Dean, Goodman, Zachary, Schaefer, Felicity, Carbarns, Ian R. I., Lamle, Sophie, Martic, Miljen, Naoumov, Nikolai V., Brass, Clifford A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941046/
https://www.ncbi.nlm.nih.gov/pubmed/36797481
http://dx.doi.org/10.1038/s41591-022-02200-8